One of the most recent evaluations of HRQoL and tolerability in psoriasis suggested that IL-17 and IL-23 inhibitors provide the most benefit in terms of quality of life, while the occurrence of serious adverse events is not significantly more frequent than in patients treated with placebo [23, 24]. Here, IL17A is linked to psoriasis.